The Quick Guide to ADHD Follow-Up SOAP Note

ADHD follow-up visits present a documentation challenge that most other conditions don't: you're prescribing controlled substances to patients who feel fine, often to children, while needing to justify continued treatment month after month.

Get the documentation wrong and you face denied prescriptions, DEA scrutiny, insurance audits questioning medical necessity, or even legal liability if something goes wrong.

I've worked with psychiatrists, pediatricians, and family medicine doctors who dread writing these notes because the stakes feel so high.

One provider told me she spends 15 minutes on a routine ADHD follow-up visit but 25 minutes documenting it properly because she's terrified of missing something that could trigger an audit.

The anxiety is understandable.

ADHD medication management involves Schedule II controlled substances with strict prescribing regulations, insurance companies that deny refills without proper documentation, and families who depend on medication continuity for their child's academic success.

Your notes need to demonstrate ongoing medical necessity, appropriate monitoring for side effects and diversion risk, and evidence that treatment is actually working—all while being efficient enough to sustain in a busy practice.

That's exactly why I built SOAP Notes Doctor: to help providers document ADHD follow-ups thoroughly without the documentation burden overwhelming their practice.

Why ADHD Follow-Up Documentation Is Uniquely Challenging

Unlike documenting a blood pressure check or diabetes visit, ADHD follow-ups involve multiple layers of requirements:

DEA and state medical boards scrutinize controlled substance prescribing patterns and can investigate providers whose documentation doesn't support medical necessity.

Insurance companies require specific elements in ADHD notes: symptom assessment using standardized scales, monitoring for side effects, documentation of functional improvement, and evidence that non-pharmacologic interventions have been tried.

Prior authorizations for brand-name medications get denied unless your notes clearly document failed trials of generic alternatives or specific contraindications.

Families expect prescription refills at every visit, but you need documentation showing the medication is helping and being used appropriately.

Legal protection requires documenting that you've assessed for diversion risk, monitored growth in children, screened for substance abuse, and educated about proper medication storage.

Your ADHD follow-up note is simultaneously a clinical document, a legal record, a controlled substance justification, and an insurance compliance form.

No wonder they take so long to write.

Essential Components of Every ADHD Follow-Up SOAP Note

Based on reviewing countless ADHD notes that passed (and failed) audits, here are the non-negotiable elements:

Response to Current Medication

You must document whether the current dose and medication are actually helping. Not just "doing well on meds" but specific functional improvements in target areas: school performance, focus during homework, completion of tasks, social interactions.

Side Effect Monitoring

Insurance auditors specifically look for documentation that you asked about common stimulant side effects: appetite suppression, sleep disturbances, irritability, weight changes, cardiovascular symptoms, tics, mood changes.

Adherence and Diversion Risk Assessment

With controlled substances, you need documentation that medication is being taken as prescribed, stored securely, and not being diverted. Ask about who administers medication, where it's stored, whether dosing is consistent.

Functional Impairment Assessment

ADHD is diagnosed based on functional impairment, and continued treatment requires ongoing documentation that impairment persists when unmedicated or improves with medication.

Standardized Rating Scales

Insurance companies increasingly require periodic use of validated ADHD rating scales (Vanderbilt, Conners, ADHD-RS) to objectively measure symptoms and treatment response.

Alternative Treatment Consideration

Notes should reflect that you've considered or are using behavioral interventions, accommodations, or non-stimulant options—not just reflexively prescribing stimulants.

Let me show you what this looks like in actual follow-up notes.

Example 1: Routine ADHD Follow-Up, Child Stable on Medication

Patient: 10-year-old male
Diagnosis: ADHD, Combined Type
Current Medication: Methylphenidate ER 27mg daily
Visit: 3-month follow-up

S – Subjective:

Patient presents with mother for routine ADHD medication management. Mother reports medication continues to be effective for focus and attention at school. Teacher feedback indicates sustained improvement in classroom behavior, staying on task during lessons, and completing assignments. Recent progress report shows grades improved from C's to B's since starting medication 6 months ago. Homework completion has improved significantly, now able to finish assignments independently within 45 minutes (previously took 2+ hours with constant redirection).

Medication taken once daily at 7 AM before school. Mother administers medication and keeps locked in cabinet. No missed doses. Denies sharing, selling, or loss of medication. Medication wears off by evening, some difficulty with homework focus after school. Weekend dosing consistent.

Side effects: Appetite decreased during school day but eats well at dinner and before bed. Weight stable. No trouble falling asleep (bedtime 9 PM, asleep by 9:30 PM). No mood changes, irritability, or emotional lability. Denies tics, chest pain, or palpitations. Energy level good, playing soccer without cardiovascular concerns.

O – Objective:

Vital Signs: BP 102/64, HR 78, Wt 72 lbs (50th percentile, stable from last visit), Ht 54 inches
General: Well-appearing, cooperative, age-appropriate behavior
Mental Status: Alert, oriented, good eye contact, speech normal rate and volume, mood euthymic, affect appropriate, thought process linear and goal-directed, no psychotic symptoms
Cardiovascular: Regular rate and rhythm, no murmurs
Neurological: No tics observed

ADHD Rating Scale (completed by mother): Inattention subscale 12/27 (improved from 22/27 at baseline), Hyperactivity subscale 8/27 (improved from 19/27 at baseline)

Teacher Vanderbilt: Performance score improved, inattention items scored 1-2 (occasionally) versus 3-4 (very often) at baseline

Prescription Monitoring Program (PMP) checked: No controlled substances from other providers

A – Assessment:

ADHD, Combined Type, currently well-controlled on methylphenidate ER 27mg daily. Patient demonstrating clear functional improvement in academic performance, task completion, and classroom behavior. Treatment response documented by both parent and teacher rating scales showing clinically significant improvement from baseline. Medication well-tolerated with minimal side effects. Growth appropriate, no cardiovascular concerns. No evidence of medication diversion or misuse. Family appropriately storing and administering medication. Some evening symptom return as medication wears off, but family not requesting coverage for evening activities at this time.

P – Plan:

Medication: Continue methylphenidate ER 27mg daily. Provided 90-day prescription (discussed secure storage and proper disposal of unused medication). No dose adjustment needed at this time given good response and tolerability.

Monitoring: Discussed potential option of adding short-acting afternoon dose if evening homework difficulties worsen, but family prefers to continue current regimen for now. Continue monitoring appetite and weight—mother to offer protein-rich breakfast before medication and high-calorie evening snack.

Behavioral Support: Encouraged continued use of organizational strategies and behavioral support at home. Patient benefiting from structured homework time and use of visual schedules.

School Communication: Mother to follow up with teacher regarding possible 504 plan accommodations including preferential seating and extended time for tests, even though symptoms controlled.

Follow-up: Return in 3 months for continued ADHD management and medication monitoring. Sooner if concerns about efficacy, side effects, or need for dose adjustment. Mother to complete Vanderbilt rating scale before next visit. Will recheck height, weight, blood pressure, and heart rate at all visits per standard monitoring guidelines.

Education: Reviewed importance of medication consistency, secure storage to prevent diversion, and monitoring for cardiovascular symptoms during physical activities. Family verbalized understanding.

---

Example 2: Medication Not Working, Dose Adjustment Needed

Patient: 16-year-old female
Diagnosis: ADHD, Predominantly Inattentive Type
Current Medication: Amphetamine/dextroamphetamine 10mg daily
Visit: Monthly follow-up, requested earlier due to concerns

S – Subjective:

Patient and parent report current medication dose no longer providing adequate symptom control. Patient started on 10mg mixed amphetamine salts 8 weeks ago with initial good response, but over past 3 weeks symptoms have returned. Describes difficulty maintaining focus during classes, particularly afternoon periods. Mind "wanders constantly" during lectures. Taking 2-3 hours to complete homework that should take 45 minutes. Missing important details in assignments.

Patient denies misusing medication or taking extra doses. Takes medication at 7 AM with breakfast daily. Medication seems to wear off by noon. Parent confirms consistent administration and secure storage. No medication sharing or diversion. Pill counts match expected usage.

No concerning side effects noted. Appetite decreased during morning but eats normally by evening. Sleep quality good, falling asleep easily at 10:30 PM. Mood stable, no irritability or mood swings. Patient denies using alcohol, marijuana, or other substances. No concerns about heart racing or chest pain.

O – Objective:

Vital Signs: BP 112/68, HR 72, Wt 128 lbs (stable), Ht 64 inches
General: Casually dressed, cooperative, fidgety during interview
Mental Status: Alert, oriented, fair eye contact, speech slightly rapid, mood "frustrated," affect congruent, no evidence of psychosis, thought process somewhat tangential when describing school challenges
Cardiovascular: RRR, no murmurs

ADHD Self-Report Scale: Score 42/72 (moderate symptoms, increased from 28/72 at last visit)

Recent report card: Grades declined from B's to C's over past marking period

UDS: Negative for substances (routine screening for adolescent on stimulants)

PMP: No other controlled substances, no early refills

A – Assessment:

ADHD, Predominantly Inattentive Type, inadequately controlled on current dose of amphetamine/dextroamphetamine 10mg daily. Patient initially responded well but now experiencing symptom breakthrough, likely related to need for dose titration. Short duration of action causing afternoon symptom return. No evidence of medication diversion, misuse, or tolerance related to inappropriate use. Decline in academic performance correlating with symptom return. No contraindications to dose increase. Patient demonstrating good insight into symptoms and treatment needs.

P – Plan:

Medication Adjustment: Increased amphetamine/dextroamphetamine to 15mg daily. Explained that gradual titration is standard approach and this remains within typical therapeutic range. Alternative would be switching to extended-release formulation for longer coverage. Patient and parent prefer trying dose increase first.

Monitoring: Patient to monitor for any increase in side effects with higher dose, particularly sleep disturbance, appetite suppression, anxiety, or cardiovascular symptoms. Instructed to call if experiences chest pain, palpitations, or significant mood changes.

Substance Use Screening: Reviewed risks of stimulant use with alcohol and other substances. Patient denies current use. Will continue periodic UDS screening as standard of care for adolescent stimulant management.

Academic Support: Recommended patient meet with school counselor to discuss potential accommodations under 504 plan, including extended time for tests, note-taking assistance, and permission to take movement breaks.

Follow-up: Return in 4 weeks to assess response to dose increase. If symptoms not adequately controlled at 15mg, will consider transition to long-acting formulation or addition of afternoon booster dose. Will reassess ADHD rating scale at next visit.

Parent Education: Reviewed continued importance of secure medication storage, monitoring for signs of diversion or misuse, and maintaining open communication about medication effects. Parent verbalized understanding and agreement with plan.

---

Example 3: Adult ADHD, First Follow-Up After Starting Medication

Patient: 28-year-old female
Diagnosis: ADHD, Combined Type (newly diagnosed)
Current Medication: Atomoxetine 40mg daily (non-stimulant)
Visit: 6-week follow-up after initiation

S – Subjective:

Patient returns for first follow-up after starting ADHD treatment 6 weeks ago. Diagnosed with ADHD 2 months ago after years of struggling with focus, organization, and time management. Started on atomoxetine (non-stimulant) rather than stimulant given history of anxiety and patient preference to avoid controlled substances.

Reports noticeable improvement in ability to start and complete tasks at work. Previously would become overwhelmed and procrastinate on projects; now able to break tasks into steps and follow through. Able to maintain focus during meetings without mind wandering constantly. Morning routine improved—able to get ready without getting sidetracked. Still struggles with organization and time management but feels these are improving.

Medication taken consistently each morning with breakfast. No missed doses. Side effects: Mild nausea for first week that resolved, some dry mouth, no appetite changes. Sleep quality actually improved compared to baseline. Anxiety symptoms stable, not worsened by ADHD medication. No suicidal ideation.

Patient also started seeing therapist for CBT focused on ADHD organizational skills and time management strategies. Finding this combination helpful.

O – Objective:

Vital Signs: BP 118/76, HR 68, Wt 142 lbs (stable)
General: Well-groomed, appropriate dress, engaged and attentive during visit
Mental Status: Alert, oriented, good eye contact maintained throughout interview (noted improvement from initial evaluation), speech normal rate, mood "much better," affect brightened, thought process organized and linear, denies SI/HI, no psychotic symptoms

Adult ADHD Self-Report Scale (ASRS): Score 32/72 (improved from 52/72 at baseline, indicating moderate improvement)

Work performance: Patient reports recent positive feedback from supervisor on project completion and meeting deadlines (had been receiving warnings prior to treatment)

A – Assessment:

ADHD, Combined Type, responding well to atomoxetine 40mg daily. Patient demonstrating functional improvement in occupational performance, task initiation and completion, and sustained attention. Rating scale improvement supports clinical response. Medication well-tolerated without significant side effects. Patient appropriately engaging in multimodal treatment including therapy for skill-building. Anxiety symptoms stable and not exacerbated by ADHD treatment. Patient demonstrating good treatment adherence and insight.

Given positive response but not yet optimal symptom control, patient may benefit from dose increase. Atomoxetine can be titrated to 80-100mg daily based on weight and response.

P – Plan:

Medication Adjustment: Increased atomoxetine to 60mg daily. Explained that therapeutic effect continues to build over 6-12 weeks at optimal dose. Full benefits may not be apparent for another 4-6 weeks at higher dose. Patient agreeable to gradual titration approach.

Continued Monitoring: Patient to monitor for any side effects, particularly mood changes, as atomoxetine rarely can affect mood in adults. Instructed to call immediately if experiences worsening depression or any suicidal thoughts. Will screen for this at each visit.

Behavioral Strategies: Patient to continue weekly therapy focusing on ADHD-specific skill building. Discussed importance of external structure: using calendar apps, timers, and organizational systems. Provided handout on adult ADHD management strategies.

Stimulant Discussion: Reviewed that if symptom control remains suboptimal at maximum atomoxetine dose (100mg), alternative options include stimulant medications. Patient currently prefers non-stimulant approach but open to reconsideration if needed.

Workplace Accommodations: Discussed potential benefits of requesting reasonable accommodations under ADA, such as written instructions for complex tasks, flexible break schedules, or noise-reducing headphones. Patient to consider whether this would be helpful.

Follow-up: Return in 8 weeks after dose stabilization at 60mg. Will reassess symptoms using ASRS and discuss whether further titration needed. Long-term plan is quarterly visits once medication optimized. Patient to call sooner if concerns about efficacy, side effects, or need for earlier follow-up.

Documentation: Provided letter documenting ADHD diagnosis for patient's records (patient requested for workplace accommodation purposes). Reviewed privacy and when diagnosis disclosure is optional versus required.

---

Critical Documentation Elements for Controlled Substance Prescribing

When prescribing stimulant medications, your notes need specific elements to withstand DEA scrutiny and medical board review:

Medical Necessity Documentation

Every stimulant prescription requires documented evidence that medication is medically necessary. This means documenting ongoing functional impairment and response to treatment, not just "refill requested."

Informed Consent

Document that you've discussed risks of stimulant medications: potential for dependence, cardiovascular risks, growth suppression in children, proper storage to prevent diversion.

Prescription Drug Monitoring Program (PDMP) Checks

Many states require checking PDMP before prescribing controlled substances. Document that you checked and found no concerning patterns.

Pill Counts and Diversion Screening

Periodic pill counts (announced or unannounced) and questions about medication security help document appropriate use. Document these conversations.

Treatment Agreements

Consider having patients/families sign stimulant treatment agreements outlining responsibilities and grounds for discontinuation. Reference this in your note.

Alternative Treatment Documentation

Notes should show you've considered or recommended non-pharmacologic interventions: behavioral therapy, organizational coaching, school accommodations.

Common Documentation Mistakes That Trigger Audits

After reviewing hundreds of ADHD notes flagged during audits, here are the patterns that cause problems:

"Doing well on meds, continue current dose" → This doesn't document medical necessity, symptom monitoring, or side effect screening. Insurance sees this as reflexive prescribing.

No documented functional impairment → ADHD diagnosis requires functional impairment in multiple settings. Follow-up notes should reference ongoing impairment or improvement with treatment.

Missing side effect screening → When adverse events occur (growth suppression, cardiovascular issues), notes that never documented asking about these symptoms create liability.

Prescribing without height/weight documentation in children → Growth monitoring is standard of care for stimulant treatment. Missing this data suggests inadequate monitoring.

No cardiovascular screening → Notes should document asking about chest pain, palpitations, syncope, especially given rare but serious cardiac risks.

Unclear why branded medication is necessary → Prior authorizations get denied without documentation of failed generic trials or specific contraindications to generics.

How Insurance Companies Review ADHD Follow-Up Notes

Insurance auditors look for specific elements when reviewing ADHD documentation:

Symptom Assessment Using Validated Tools: They want to see Vanderbilt scales, Conners ratings, ADHD-RS scores—not just subjective descriptions.

Documentation of Functional Improvement: Notes must show how medication improves real-world functioning: grades, job performance, relationship quality, daily task completion.

Appropriate Visit Frequency: Stimulant prescriptions typically require monthly visits initially, then can extend to quarterly once stable. Notes should justify visit frequency.

Trial of Non-Stimulant Options: For high-dose stimulants or long-term treatment, insurance may question why non-stimulant alternatives weren't tried. Document this reasoning.

Age-Appropriate Monitoring: Children need growth tracking, adolescents need substance abuse screening, adults need cardiovascular monitoring. Notes should reflect appropriate age-specific monitoring.

Documentation Strategies That Save Time Without Cutting Corners

Here's what I've learned from helping providers streamline ADHD documentation:

Use templates with required elements built in so you don't forget critical components. SOAP Notes Doctor automatically includes all essential monitoring elements.

Document negative findings efficiently: "ROS negative for chest pain, palpitations, syncope, tics, or mood changes" covers multiple side effects concisely.

Reference rating scales by score: "Vanderbilt parent scale score 18/54 (improved from 38/54 baseline)" provides objective data efficiently.

Create standard medication education language: Document once that you discussed proper storage, diversion prevention, and risks—then reference "standard stimulant counseling provided" at follow-ups.

Use standing orders for monitoring: Document that patient will have height, weight, BP, and HR checked at every visit per standing protocol.

Batch similar documentation: If you see multiple ADHD follow-ups in one day, use consistent structure across notes for efficiency while personalizing clinical details.

Why SOAP Notes Doctor Works Particularly Well for ADHD

ADHD follow-up documentation has so many required elements that it's easy to miss something important.

SOAP Notes Doctor's ADHD templates automatically include:

• Symptom assessment with functional impact
• Comprehensive side effect screening
• Growth and vital sign documentation
• Diversion risk assessment
• Rating scale integration
• Medication adherence evaluation
• Age-appropriate monitoring elements
• Controlled substance prescribing justification

You record the clinical details—what the patient reported, what you observed, what you discussed.

The system ensures every required element gets documented properly without you needing to remember a checklist.

Try it at soapnotes.doctor and see how much faster you can complete thorough ADHD documentation.

Final Thoughts

ADHD follow-up documentation is more complex than it should be, but the requirements exist for legitimate reasons: controlled substance accountability, quality monitoring, legal protection, and insurance oversight.

The good news is that once you know what elements must be included, you can document efficiently without spending excessive time on each note.

Whether you document manually or use SOAP Notes Doctor, make sure every ADHD follow-up note includes: current symptom status, functional impact, side effect screening, adherence assessment, and rationale for continued treatment.

These elements satisfy regulatory requirements while creating notes that actually support quality patient care.

Your ADHD patients deserve excellent treatment, and your documentation should reflect the thoughtful care you're providing.

---

Ready to streamline your ADHD follow-up documentation?
Visit soapnotes.doctor and generate compliant ADHD notes in minutes.